221 related articles for article (PubMed ID: 19877972)
1. An open study of adjunct OROS-methylphenidate in children and adolescents who are atomoxetine partial responders: I. Effectiveness.
Wilens TE; Hammerness P; Utzinger L; Schillinger M; Georgiopoulous A; Doyle RL; Martelon M; Brodziak K
J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):485-92. PubMed ID: 19877972
[TBL] [Abstract][Full Text] [Related]
2. An open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics.
Hammerness P; Georgiopoulos A; Doyle RL; Utzinger L; Schillinger M; Martelon M; Brodziak K; Biederman J; Wilens TE
J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):493-9. PubMed ID: 19877973
[TBL] [Abstract][Full Text] [Related]
3. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
[TBL] [Abstract][Full Text] [Related]
4. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
Su Y; Yang L; Stein MA; Cao Q; Wang Y
J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
[TBL] [Abstract][Full Text] [Related]
5. Atomoxetine and methylphenidate treatment in children with ADHD: the efficacy, tolerability and effects on executive functions.
Yildiz O; Sismanlar SG; Memik NC; Karakaya I; Agaoglu B
Child Psychiatry Hum Dev; 2011 Jun; 42(3):257-69. PubMed ID: 21165694
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study.
Kemner JE; Starr HL; Ciccone PE; Hooper-Wood CG; Crockett RS
Adv Ther; 2005; 22(5):498-512. PubMed ID: 16418159
[TBL] [Abstract][Full Text] [Related]
7. Effects of Atomoxetine and Osmotic Release Oral System-Methylphenidate on Executive Functions in Patients with Combined Type Attention-Deficit/Hyperactivity Disorder.
Ince Tasdelen B; Karakaya E; Oztop DB
J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):494-500. PubMed ID: 26218871
[TBL] [Abstract][Full Text] [Related]
8. Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.
Wu EQ; Birnbaum HG; Zhang HF; Ivanova JI; Yang E; Mallet D
J Manag Care Pharm; 2007 Sep; 13(7):561-9. PubMed ID: 17874862
[TBL] [Abstract][Full Text] [Related]
9. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
[TBL] [Abstract][Full Text] [Related]
10. Multicenter, randomized, open-label study of OROS methylphenidate versus atomoxetine: treatment outcomes in African-American children with ADHD.
Starr HL; Kemner J
J Natl Med Assoc; 2005 Oct; 97(10 Suppl):11S-16S. PubMed ID: 16350601
[TBL] [Abstract][Full Text] [Related]
11. Comparative study of OROS-MPH and atomoxetine on executive function improvement in ADHD: a randomized controlled trial.
Yang L; Cao Q; Shuai L; Li H; Chan RC; Wang Y
Int J Neuropsychopharmacol; 2012 Feb; 15(1):15-26. PubMed ID: 22017969
[TBL] [Abstract][Full Text] [Related]
12. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
Garnock-Jones KP; Keating GM
Paediatr Drugs; 2009; 11(3):203-26. PubMed ID: 19445548
[TBL] [Abstract][Full Text] [Related]
13. Differential Treatment Effects of Methylphenidate and Atomoxetine on Executive Functions in Children with Attention-Deficit/Hyperactivity Disorder.
Wu CS; Shang CY; Lin HY; Gau SS
J Child Adolesc Psychopharmacol; 2021 Apr; 31(3):187-196. PubMed ID: 33890819
[No Abstract] [Full Text] [Related]
14. OROS-methylphenidate efficacy on specific executive functioning deficits in adults with ADHD: a randomized, placebo-controlled cross-over study.
Bron TI; Bijlenga D; Boonstra AM; Breuk M; Pardoen WF; Beekman AT; Kooij JJ
Eur Neuropsychopharmacol; 2014 Apr; 24(4):519-28. PubMed ID: 24508533
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of one-year pharmacological treatment of adult attention-deficit/hyperactivity disorder (ADHD): an open-label prospective study of time in treatment, dose, side-effects and comorbidity.
Fredriksen M; Dahl AA; Martinsen EW; Klungsøyr O; Haavik J; Peleikis DE
Eur Neuropsychopharmacol; 2014 Dec; 24(12):1873-84. PubMed ID: 25453480
[TBL] [Abstract][Full Text] [Related]
16. A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability.
Treuer T; Gau SS; Méndez L; Montgomery W; Monk JA; Altin M; Wu S; Lin CC; Dueñas HJ
J Child Adolesc Psychopharmacol; 2013 Apr; 23(3):179-93. PubMed ID: 23560600
[TBL] [Abstract][Full Text] [Related]
17. [Effectiveness and safety of methylphenidate and atomoxetine for attention deficit hyperactivity disorder: a systematic review].
Lv XZ; Shu Z; Zhang YW; Wu SS; Zhan SY
Zhongguo Dang Dai Er Ke Za Zhi; 2011 May; 13(5):365-9. PubMed ID: 21575338
[TBL] [Abstract][Full Text] [Related]
18. Long-term quality-of-life and functioning comparison of atomoxetine versus other standard treatment in pediatric attention-deficit/hyperactivity disorder.
Fuentes J; Danckaerts M; Cardo E; Puvanendran K; Berquin P; De Bruyckere K; Montoya A; Quail D; Escobar R
J Clin Psychopharmacol; 2013 Dec; 33(6):766-74. PubMed ID: 23963057
[TBL] [Abstract][Full Text] [Related]
19. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
[TBL] [Abstract][Full Text] [Related]
20. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.
Gibson AP; Bettinger TL; Patel NC; Crismon ML
Ann Pharmacother; 2006 Jun; 40(6):1134-42. PubMed ID: 16735655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]